Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Epigral announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: YoY Revenue grew by 20% to Rs 631 crore, on account of volume growth from Derivative products. Revenue contribution from Derivatives & Specialty business increased to 52% in Q4FY25 vs 48% in Q4FY24. EBITDA grew by 12% to Rs 173 crore vs Rs 155 crore in Q4FY24, and EBITDA margin stood at 28%. PAT rose by 13% to Rs 87 crore. ROCE grew to 25% as on 31st March 2025 vs 18% as on 31st March 2024 due to improvement in earnings. Net Debt/EBITDA significantly reduced to 0.7x as on 31st March 2025 vs 2.0x as on 31st March 2024 on account of improvement in EBITDA and reduction in net debt. FY25 Financial Highlights: Highest ever revenue of Rs 2,565 crore, growth of 33% on account of volume growth from Derivative products. Revenue contribution from Derivatives & Specialty business increased to 54% in FY25 vs 45% in FY24. EBITDA grew by 48% to Rs 711 crore vs Rs 481 crore in FY24. EBITDA margin stood at 28% in FY25 vs 25% in FY24 on account of a better product mix, led by contribution from new projects. PAT jumped by 82% to Rs 357 crore. Maulik Patel, Chairman and Managing Director, Epigral, said: “We ended FY25 with the highest ever revenue of Rs 2,565 crore, a growth of 33% compared to the previous year. This growth is on account of a volume rise of 11%, majorly from high-value products. Derivatives & Specialty business volume grew by around 24% in FY25, and its contribution to revenue touched 54% compared to 45% in FY24. Considering the growth opportunity, we further announced expanding our CPVC and Epichlorohydrin capacity, which are expected to be commissioned in the first half of FY27 and will contribute from FY27 onwards. Once these projects reach optimum utilisation, our integrated complex will further strengthen. We are geared up and strengthened our position, to grow further, by focusing on import substitute products, further diversifying and increasing Derivatives & Specialty business and with prudence allocation of capital, rewarding our stakeholders.” Result PDF
Conference Call with Gravita India Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Yasho Industries announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Total Revenue: Rs 18,553 lakh compared to Rs 17,233 lakh during Q4FY24, change 7.7%. EBITDA: Rs 3,559 lakh compared to Rs 3,145 lakh during Q4FY24, change 13.2%. EBITDA margin: 19.2% for Q4FY25. PAT: Rs 503 lakh compared to Rs 1,794 lakh during Q4FY24. PAT margin: 2.7% for Q4FY25. FY25 Financial Highlights: Total Revenue: Rs 67,725 lakh compared to Rs 60,097 lakh during FY24, change 12.7%. EBITDA: Rs 11,829 lakh compared to Rs 10,721 lakh during FY24, change 10.3%. EBITDA margin: 17.5% for FY25. PAT: Rs 611 lakh compared to Rs 5,794 lakh during FY24. PAT margin: 0.9% for FY25. Business Highlights: Industrial business accounted for 85% of the total revenue for the quarter. Exports contributed 67% despite a challenging global scenario. The volumes have increased by 20% on YoY basis for the quarter as compared to 8% in Q3FY25. The Pakhajan facility has streamlined its operations with ~50% capacity utilization from March, 2025. Parag Jhaveri, Managing Director & CEO said: “The global chemical industry continues to remain volatile. We continue to face pressure on selling prices due to the current global uncertainty. Despite these challenges, we are confident to achieve 40-50% revenue growth in FY 26 while maintaining current margins. Our US warehouse is now operational. We have also commenced a marginal capacity expansion for products where we see strong growth opportunities.” Result PDF